E
Estrella Immunopharma, Inc. (ESLA)
NCM – Real Time Price. Currency in USD
1.21
-0.05 (-3.97%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.21
-0.05 (-3.97%)
At close: May 12, 2026, 4:00 PM EDT
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
| Name | Position |
|---|---|
| Dr. Cheng Liu Ph.D. | CEO, President & Director |
| Mr. Jiandong Xu | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | 10-K/A | ea0288591-10ka1_estrella.htm |
| 2026-03-18 | 10-K | ea0276230-10k_estrella.htm |
| 2026-01-22 | S-1/A | ea0269161-03.htm |
| 2026-01-16 | S-1/A | ea0269161-02.htm |
| 2026-01-13 | 8-K | ea027282201-8k_estrellaimmu.htm |
| 2026-01-06 | 8-K | ea0271975-8k_estrella.htm |
| 2025-12-22 | S-1 | ea0269161-01.htm |
| 2025-12-04 | 8-K | ea0268496-8k_estrella.htm |
| 2025-11-12 | 10-Q | ea0262756-10q_estrella.htm |
| 2025-11-06 | 8-K | ea0264099-8k_estrella.htm |